 To evaluate the safety for the combination of Rivaroxaban and Ticagrel versus triple antithrombotic regimen Vitamin K Antagonist VKA, Clopigogrel and Aspirin in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention PCI. 